The emerging role of precision medicine in the treatment of endometrial cancer

Keyphrases

• Tumor 100%
• Molecular Pathways 100%
• Endometrial Cancer 100%
• Precision Medicine 100%
• Recurrent Endometrial Cancer 100%
• Clinical Trials 50%
• Mammalian Target of Rapamycin (mTOR) 50%
• Angiogenesis 50%
• Treatment Regimen 50%
• Molecular Characterization 50%
• PubMed 50%
• Conventional Chemotherapy 50%
• Her2neu 50%
• Early Disease 50%
• Gynecologic Oncology Group 50%
• Immune Checkpoint Inhibitors 50%
• Gynecologic Malignancies 50%
• Endocrine Therapy 50%
• Clinical Benefit 50%
• Promising Treatment 50%
• AKT1 50%
• Medroxyprogesterone Acetate 50%
• Cure Rate 50%
• Uterine Cancer 50%
• Expert Commentary 50%
• Area Cover 50%
• Letrozole 50%
• Anastrozole 50%
• Google Scholar 50%
• Extensive Literature Search 50%
• Change in Treatment 50%
• Molecular Landscape 50%
• Real-time Changes 50%
• Megace 50%
• Continuous Innovation 50%

Medicine and Dentistry

• Personalized Medicine 100%
• Uterine Cancer 100%
• Neoplasm 50%
• Clinical Trial 25%
• Cancer 25%
• Immunotherapy 25%
• Angiogenesis 25%
• Epidermal Growth Factor Receptor 25%
• Hormone Therapy 25%
• Gynecological Oncology 25%
• Immune Checkpoint Inhibitor 25%
• Vasculotropin 25%
• Tamoxifen 25%
• Depo-Provera 25%
• Letrozole 25%
• Anastrozole 25%
• Protein Kinase B 25%
• Megestrol Acetate 25%
• Medroxyprogesterone Acetate 25%
• Diseases 25%